hematopoietic stem cells

[PureTech Health plc] PureTech Health plc announced that its Founded Entity, Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, Vor's lead engineered hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukemia.

[Blood Advances] Investigators evaluated dasatinib-based two-step induction with the primary endpoint of three-year event-free survival as treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

[Cell Reports] Researchers demonstrated by clonal assays and single-cell transcriptomics that rare hemogenic endothelium (HE) with functional HSC potential in the early murine embryo were distinct from more abundant HE with multilineage hematopoietic potential that failed to generate HSCs.

[Cell Reports] Using single-cell transcriptomics, investigators defined gene signatures that distinguished nascent HSCs from embryonic blood progenitors. Applying a lineage-tracing approach to selectively track HSC output in situ, they found significantly delayed lymphomyeloid contribution.

[Blood Cancer Journal] Investigators discuss the role and importance of inflammasomes and immune pathways in myeloid malignancies, particularly myelodysplastic syndromes/acute myeloid leukemia, to better understand the disease pathophysiology and decipher the scope of therapeutic interventions.

[Leukemia] Researchers showed that pro-inflammatory oncostatin M (OSM) was an important regulator of HSC niches in the bone marrow (BM). OSM up-regulated E-selectin expression on BM endothelial cells indirectly increasing HSC proliferation.